ZyVersa Therapeutics Announces Publication in Molecular Neurobiology Reinforcing Data Demonstrating That Inflammasome ASC Inhibitor IC 100 Attenuates the Inflammatory Response Causing Neuronal Damage in Multiple Sclerosis Model, Potentially Providing Neuroprotection
November 01, 2023 08:07 ET | ZyVersa Therapeutics
NLRP3 Inflammasome Inhibition Alleviates Neurological Impairment in the Brain of MS Mouse Model, Reinforcing Published Data for IC 100 in MS Mouse Model.